Part three of this four part video series from J&J highlights focuses on long-acting injectable (LAI) antipsychotics as a treatment option for schizophrenia. It discusses how LAIs may support treatment adherence, provide stability, and reduce the need for daily medication. A patient advocate shares personal experiences, and the session explores how LAIs could influence independence, routine, and the treatment environment. The event also covers resources, self-advocacy, and strategies for improving communication between patients and healthcare professionals when making treatment decisions.
To learn more, watch the video here.
Contributor: Johnson & Johnson – Dr. Christoph Correll, Dr. Leslie Citrome, Max Guttman (patient)
